Skincare Options Emerge for Post-Weight-Loss Sagging
Beauty brands are developing new products and devices to help address facial skin changes following rapid weight loss.
Updated on Oct. 28, 2026 in Weight Loss
Live Poll
Do you believe beauty companies should specifically market new products to address effects of weight-loss drugs?
Beauty companies are increasingly developing skincare products and devices specifically to manage facial skin sagging associated with rapid weight loss. This trend follows a significant rise in the use of GLP-1 obesity treatments, which can cause facial fat loss.
Why it matters
Rapid weight loss can lead to visible skin laxity as facial fat decreases, prompting a shift in the cosmetic industry to address these specific changes. As the prevalence of weight loss medications grows, so does the demand for targeted elasticity management tools.
A PwC analysis confirms that U.S. household GLP-1 usage rose to 21% in May 2026, up from 9% in January 2025. While sales of elastic-focused products like the Medicube ampoule have surpassed 1 million units, the long-term clinical impact of these treatments on skin structural integrity remains unknown.
The players
L'Oréal
A global beauty conglomerate managing brands like SkinCeuticals and Kiehl's that are currently targeting post-weight-loss skin elasticity.
Galderma
A pharmaceutical company specializing in medical aesthetics and dermatology that is investigating the use of Sculptra and Restylane for post-weight-loss patients.
Amorepacific
A South Korean beauty and cosmetics company that recently launched the Sumalift device for skin management.
Medicube
A skincare brand known for its home-use beauty devices and topicals, including the widely sold EGF NAD Elastic Ampoule.
The details
Companies are leveraging peptide materials and adiponectin activators to improve skin appearance, while also repurposing existing aesthetic staples like collagen promoters and hyaluronic acid fillers. These products are designed to support skin elasticity as individuals lose facial volume. Furthermore, home beauty devices, such as the Sumalift, aim to provide non-invasive maintenance for users experiencing post-weight-loss skin changes.
Timeline
January 2025: GLP-1 drug usage reached 9% of U.S. households.
May 2026: GLP-1 drug usage rose to 21% of U.S. households.
September 2026: Amorepacific released the Sumalift beauty device.
Late September 2026: Medicube ampoule sales reached 1 million units.
Health Landscape
The clinical aesthetics market is currently valued at 700 million dollars and is projected to reach 2 billion dollars by 2031. This expansion mirrors the broader increase in obesity treatment adoption documented in the PwC report on GLP-1 usage trends.
If you notice skin sagging after significant weight loss, it is worth discussing options with a dermatologist to determine if evidence-based clinical treatments are appropriate for your skin type. Avoid starting new aesthetic regimens without first confirming they are safe for your specific health history.
The takeaway
Rapid weight loss may lead to changes in facial skin elasticity as fat volume decreases. Focus on maintaining a healthy, balanced diet and consult your physician or a dermatologist to discuss skin health goals before investing in new aesthetic products or home devices.
Further reading
For more on managing body changes after weight loss, visit our Weight Loss section.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you believe beauty companies should specifically market new products to address effects of weight-loss drugs?
